News: Salix Pharmaceuticals Ltd (SLXP.OQ)

SLXP.OQ on NASDAQ Stock Exchange Global Select Market

159.89USD
17 Sep 2014
Price Change (% chg)

$4.02 (+2.58%)
Prev Close
$155.87
Open
$159.03
Day's High
$164.80
Day's Low
$158.25
Volume
564,302
Avg. Vol
385,826
52-wk High
$164.80
52-wk Low
$65.48

Search Stocks
Select another date:

Wed, Sep 17 2014

UPDATE 1-Market Chatter-Corporate finance press digest - Sept 17

Sept 17 - The following corporate finance-related stories were reported by media:

Market Chatter- Corporate finance press digest - Sept 17

Sept 17 - The following corporate finance-related stories were reported by media:

Exclusive: Top investors push Salix to abandon Cosmo deal - sources

NEW YORK - Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA , and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

Allergan seeks deal with Salix to fend off Valeant: WSJ

- Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said.

Allergan seeks deal with Salix to fend off Valeant - WSJ

Aug 19 - Botox maker Allergan Inc has approached Salix Pharmaceuticals Ltd and at least one other company about a potential takeover in a bid to avert the $53 billion hostile takeover from Valeant Pharmaceuticals International Inc, the Wall Street Journal said.

REFILE-BRIEF-Photocure ASA to terminate the global licensing agreement for Lumacan

(Refiles to add a code for Salix Pharmaceuticals ) Aug 18 - Photocure ASA : * Says agreed to terminate the global licensing agreement for Lumacan with Salix Pharmaceuticals * Says Will receive a payment of US$ 5M from Salix and will regain the global rights and all intellectual property to Lumacan. * Source text for Eikon * Further company coverage

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals , the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

Salix joins up with Cosmo Pharma's Irish unit for tax savings

ZURICH, July 9 - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals, the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.

BRIEF-Cosmo up 8.3 pct after Salix and subsidiary deal

July 9 - Cosmo Pharmaceuticals SpA : * Opens 8.3 percent higher following deal between subsidiary and Salix

Select another date:
Search Stocks